Articles tagged "Immunosuppression"

2018 American Transplant Congress
Single Center Experience of HLA-Related Donor Specific Antibody in Living Donor Liver Transplantation
H. Egawa,¹ Y. Kotera,¹ A. Ohmori,¹ S. Yamashita,¹ T. Kato,¹ S. Nemoto,¹ T. Ishizuka,² M. Yamamoto.¹
¹Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Clinical Laboratory, Tokyo Women's Medical University, Tokyo, Japan.
Although impact of donor specific antibody in liver transplantation has been recognized, significance of desensitization is not established yet. Our aim is to share our…
2018 American Transplant Congress
Multi-Targeting Desensitization Therapy Alters Peripheral B-Cell Homeostasis and Suppresses Recall Alloantibody Responses
I. Kim, G. Wu, N-.N. Chai, A. Klein, S. Jordan.
CTC/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Occurring of donor specific antibodies (DSA) is injurious to organ transplant. Development of immunotherapies to suppress DSA, therefore, has been one of the strategic…
2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
J. Gottlieb, C. Neurohr, J. Müller-Quernheim, H. Wirtz, B. Sill, H. Wilkens, V. Besa, C. Knosalla, M. Junge, C. Capusan, M. Strüber.
Klinik, Hannover, Germany; Klinik, München, Germany; Klinik, Freiburg, Germany; Klinik, Leipzig, Germany; Klinik, Hamburg, Germany; Klinik, Homburg, Germany; Klinik, Essen, Germany; Klinik, Berlin, Germany; Novartis Pharma, Nürnberg, Germany; Novartis Pharma, Nürnberg, Germany; Klinik, Hannover, Germany.
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…
2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
J. Shoji, J. Leung, E. Tavares, Q. Tang, F. Vincenti.
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…
2018 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
J. Breidenbach, C. Baum, P. Schroder, S. Stepkowski.
Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Science, Toledo, OH.
Background: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system, making it an attractive target for reducing chronic allograft rejection…
2018 American Transplant Congress
Non-Invasive Imaging Modalities for Immune Monitoring of Vascularized Composite Allografts Using a Translational Large Animal Model
J. Etra,¹ K. Cilwa,² G. Furtmueller,¹ A. Leto Barone,¹ K. Kolegraff,¹ E. Elster,¹ W. Lee,¹ G. Brandacher.¹
¹Department of Plastic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Naval Medical Research Center, Silver Springs, MD; ³Department of Surgery, Uniformed Services, University of Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD.
PurposeImmunological complications and skin rejection remains an obstacle in broadening the applicability of vascularized composite allotransplantation (VCA). Currently, diagnosis of rejection relies on skin biopsies…
2018 American Transplant Congress
The Impact of Immunosuppression on Mineral Metabolism One Year after Kidney Transplantation: Differences between a Mycophenolate-Based Regimen versus an mTOR-Inhibitor-Based One
D. Cucchiari,¹ S. Karam,² P. Ventura-Aguiar,¹ F. Diekmann,¹ J. Torregrosa.¹
¹Renal Transplant Unit, Hospital Clinic, Barcelona, Spain; ²Department of Medicine, Saint George Hospital University Medical Center, Beirut, Lebanon.
INTRODUCTION: after kidney transplantation, a substantial amount of patients still suffer from Mineral Bone Disorder. The role of different immunosuppressive therapies on mineral metabolism in…
2018 American Transplant Congress
Galangin Promotes Treg Development and Function
F. Liang,¹ H. Fang,¹ R. Zhang,¹ Q. Chen,² J. Ochando,³ Y. Ding,¹ J. Xu.¹
¹Department of Immunology, Capital Medical University, Beijing, China; ²Department of Thoracic Surgery, Chaoyang Hospital, Beijing, China; ³Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Introduction: FoxP3+ Treg cells are central in controlling immune responses and transplant tolerance. CD73 (ecto-5'-nucleotidase), which serves to convert AMP to adenosine, is essential for…
2018 American Transplant Congress
Successful Transplantation in a Sensitized Patient Allergic to Commercially Available Antibody Induction Agents
K. Venkatachalam, A. Malone.
Transplant Nephrology, Washington University, St. Louis, MO; Transplant Nephrology, Washington University, St. Louis, MO.
Antibody induction in renal transplantation has increased to over 80%. Rabbit anti-thymocyte globulin (rATG) is the most commonly used agent. Hypotension, rash, dyspnea with rATG…
2018 American Transplant Congress
Triptolide Reduces the Required Dose of Tacrolimus by Attenuating Inflammation, Enhancing Immunosuppression, and Increasing Donor Chimerism in a Heterotopic Hindlimb Transplantation Model
C. Gu, F. Liu, J. Yang.
Plastic and Reconstructive Surgery, Shanghai Ninth Hospital, Shanghai, China.
Background: Induction of tolerance and minimizing the toxicity of immuno- suppression are two fundamental goals in vascularized composite allotrans- plantation. Accumulating data indicate that triptolide…